Cytonics begins Phase I trial of new therapy to treat knee osteoarthritis

US-based biotechnology company Cytonics has started a Phase I clinical trial of a new therapeutic for osteoarthritis of the knee.

The first-in-human study aims to evaluate CYT-108, a recombinant protein designed to inhibit proteases that degrade cartilage in arthritic joints.